RxDoctor Payments Data

Srinivas Pavuluri, MD

Neurology · Hazlet, NJNPI 1255360020

Payments from drug & device makers

$6,942in general payments, 2019–2025

Across 454 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$1K
  • AbbVie$730
  • UCB, Inc.$727
  • Novartis$486
  • Lundbeck LLC$326
  • Johnson & Johnson$303
  • plus $3K from 34 others

What the payments were for

  • Speaking & faculty fees$481%
  • Food & beverage$6,60795%
  • Education$2874%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,942 in reported general payments places this provider in the 65th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$131,153
Medicare patients
312
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate14$175,398
Dimethyl Fumarate23$143,983
Rebif RebidoseInterferon Beta-1a/Albumin13$131,733
RytaryCarbidopa/Levodopa29$40,531
UbrelvyUbrogepant13$15,624
Oxtellar XrOxcarbazepine36$15,009
Memantine Hcl215$7,460
Carbidopa-Levodopa ErCarbidopa/Levodopa163$7,053
Gabapentin356$5,796
Rasagiline Mesylate12$4,467
Donepezil Hcl263$3,245
Levetiracetam100$3,045
Carbamazepine ErCarbamazepine15$2,374
Pramipexole DihydrochloridePramipexole Di-Hcl92$2,076
Aspirin-Dipyridamole ErAspirin/Dipyridamole12$2,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$1,122$175,39814 claims
Amneal Pharmaceuticals LLCRytary$140$40,53129 claims
AbbVieUbrelvy$730$15,62413 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$94$15,00936 claims
Upsher-smith Laboratories LLCTopiramate$140$1,625107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 521 neurology providers in New Jersey.

Other neurology in Hazlet

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →